These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 23265149)

  • 41. Diurnal variations of mouse plasma and hepatic bile acid concentrations as well as expression of biosynthetic enzymes and transporters.
    Zhang YK; Guo GL; Klaassen CD
    PLoS One; 2011 Feb; 6(2):e16683. PubMed ID: 21346810
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.
    Halilbasic E; Fuchs C; Traussnigg S; Trauner M
    Dig Dis; 2016; 34(5):580-8. PubMed ID: 27332721
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease.
    Gadaleta RM; van Mil SW; Oldenburg B; Siersema PD; Klomp LW; van Erpecum KJ
    Biochim Biophys Acta; 2010 Jul; 1801(7):683-92. PubMed ID: 20399894
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis.
    van Schaik FD; Gadaleta RM; Schaap FG; van Mil SW; Siersema PD; Oldenburg B; van Erpecum KJ
    PLoS One; 2012; 7(11):e49706. PubMed ID: 23189156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Farnesoid X receptor-dependent and -independent pathways mediate the transcriptional control of human fibroblast growth factor 19 by vitamin A.
    Jahn D; Sutor D; Dorbath D; Weiß J; Götze O; Schmitt J; Hermanns HM; Geier A
    Biochim Biophys Acta; 2016 Feb; 1859(2):381-92. PubMed ID: 26723851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Secondary (iso)BAs cooperate with endogenous ligands to activate FXR under physiological and pathological conditions.
    Zaufel A; van de Wiel SMW; Yin L; Fauler G; Chien D; Dong X; Gilmer JF; Truong JK; Dawson PA; van de Graaf SFJ; Fickert P; Moustafa T
    Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166153. PubMed ID: 33895309
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice.
    Martin IV; Schmitt J; Minkenberg A; Mertens JC; Stieger B; Mullhaupt B; Geier A
    Biol Chem; 2010 Dec; 391(12):1441-9. PubMed ID: 20868235
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation.
    Chiang JY; Pathak P; Liu H; Donepudi A; Ferrell J; Boehme S
    Dig Dis; 2017; 35(3):241-245. PubMed ID: 28249273
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bile acids and their effects on diabetes.
    Rajani C; Jia W
    Front Med; 2018 Dec; 12(6):608-623. PubMed ID: 30306382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bile acids in regulation of inflammation and immunity: friend or foe?
    Zhu C; Fuchs CD; Halilbasic E; Trauner M
    Clin Exp Rheumatol; 2016; 34(4 Suppl 98):25-31. PubMed ID: 27586800
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting FXR and FGF19 to Treat Metabolic Diseases-Lessons Learned From Bariatric Surgery.
    Bozadjieva N; Heppner KM; Seeley RJ
    Diabetes; 2018 Sep; 67(9):1720-1728. PubMed ID: 30135133
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control.
    Kuipers F; Stroeve JH; Caron S; Staels B
    Curr Opin Lipidol; 2007 Jun; 18(3):289-97. PubMed ID: 17495603
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bile Acids and Portal Hypertension.
    Arab JP; Barrera F; Arrese M
    Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s83-s86. PubMed ID: 29080345
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Marine sponge steroids as nuclear receptor ligands.
    Fiorucci S; Distrutti E; Bifulco G; D'Auria MV; Zampella A
    Trends Pharmacol Sci; 2012 Nov; 33(11):591-601. PubMed ID: 23000093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bile Acid Physiology.
    Di Ciaula A; Garruti G; Lunardi Baccetto R; Molina-Molina E; Bonfrate L; Wang DQ; Portincasa P
    Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s4-s14. PubMed ID: 29080336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bile acids via FXR initiate the expression of major transporters involved in the enterohepatic circulation of bile acids in newborn mice.
    Cui JY; Aleksunes LM; Tanaka Y; Fu ZD; Guo Y; Guo GL; Lu H; Zhong XB; Klaassen CD
    Am J Physiol Gastrointest Liver Physiol; 2012 May; 302(9):G979-96. PubMed ID: 22268101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New insights on fibrosis in Crohn's disease.
    Bailey JR; Whiting CV; Tarlton JF; Bland PW; Probert CS
    Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):497-9. PubMed ID: 23984996
    [No Abstract]   [Full Text] [Related]  

  • 58. The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling.
    Wang LX; Frey MR; Kohli R
    Front Endocrinol (Lausanne); 2021; 12():799648. PubMed ID: 35116006
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bile Acids and GPBAR-1: Dynamic Interaction Involving Genes, Environment and Gut Microbiome.
    Portincasa P; Di Ciaula A; Garruti G; Vacca M; De Angelis M; Wang DQ
    Nutrients; 2020 Nov; 12(12):. PubMed ID: 33266235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver.
    Rosales R; Romero MR; Vaquero J; Monte MJ; Requena P; Martinez-Augustin O; Sanchez de Medina F; Marin JJ
    Biochem Pharmacol; 2013 Mar; 85(6):829-38. PubMed ID: 23313557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.